Kurin

Kurin is a commercial-stage diagnostics company addressing the costly and clinically significant problem of blood culture contamination. Its flagship product, the Kurin Lock integrated into a standard blood culture collection set, automatically diverts the initial 0.15ml of blood, which is most likely to contain skin microbes, without altering clinician workflow. The company is engaged in active litigation to defend its market position, has reported record revenue, and is scaling commercial operations. Kurin's value proposition centers on improving diagnostic accuracy, supporting antibiotic stewardship, and reducing unnecessary healthcare expenditures.

Integrated blood culture collection set with a passive diversion mechanism (Kurin Lock®) that sidelines the initial 0.15ml of blood likely to contain skin contaminants, enabling collection of a cleaner specimen without altering clinician workflow.

Primary competition includes Magnolia Medical (Steripath device) and ICU Medical (Vampire system). The market also competes against the entrenched standard of care (no diversion) and simpler, lower-cost diversion pouches. Kurin differentiates with a passive, integrated set designed for minimal workflow disruption.